Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
Plos One|May 24, 2011
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersSandhya Vasan, Arlene Hurley, Sarah J Schlesinger, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
Clinical and Vaccine Immunology : CVI|December 19, 2008
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continentsMark J Boaz, Peter Hayes, Tony Tarragona, et al.
Plos One|September 30, 2010
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaWalter Jaoko, Etienne Karita, Kayitesi Kayitenkore, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
Pageof 6